- 44% of Homeowners With a Mortgage Can't Sell: Zillow
- Tim Cook Should Tell Congress to Kiss His Ass
- Millennials Won't Be Debt Free Until They Die
- Biotech Stock Mailbag: Amarin, MannKind, Palatin
- What You Wear to the Office Still Matters
Article
Auxilium CEO Goes Against Type, Buying Instead of Selling
Auxilium buys a privately held urology company as its base business weakens.
10:17AM 04/29/13
Article
Vertex CFO Rings Register on $35 Million Insider Sale
As Vertex shares surge on positive drug news, the company's CFO sells a massive stake.
07:11AM 04/24/13
Article
Celsion's Shameless Spin Job (Update)
Celsion won't let a failed liver cancer therapy stand in the way of executives collecting paychecks.
05:11PM 04/23/13
Article
Bristol Still Playing Catch-Up to Gilead in Hep C Drug Race
New hepatitis C data released Tuesday doesn't change the dynamics of the race towards all-oral therapies.
10:44AM 04/23/13
Article
Ironwood's Constipation Drug Sales Disappoint
Linzess sales of $4.5 million fall well short of Wall Street expectations.
08:18AM 04/23/13
Article
A Dendreon Shareholder Voices His Frustration at Incompetent Directors
Dendreon investor Brad Loncar is tweeting from today's Dendreon annual shareholder meeting.
12:14PM 04/22/13
Article
Amarin's Fish Oil Pill Faces Even More Exclusivity Risks
The FDA hasn't granted Vascepa three years of market exclusivity, making it easier for generics to undercut sales.
09:35AM 04/22/13
Article
Worth Repeating: Vertex Is the Next Gilead Sciences
Vertex will generate billions of dollars from its dominate cystic fibrosis drug franchise.
10:51AM 04/19/13
Article
Exact Sciences Colon Cancer Screen Results Disappoint Wall Street
Cologuard is accurate enough to pass muster with FDA but investors were looking for more.
08:17AM 04/18/13
Article
Three Cheers for Alkermes Running a Depression Study in the U.S. of A.
Alkermes plans to move ALKS 5461 into phase III studies following positive mid-stage results.
10:26AM 04/17/13
Article
MannKind's Mysterious Lung-Safety Study Is Open But Shhh...Don't Talk About It
MannKind is conducting a large, two-year safety study of its inhaled, fast-acting insulin but doesn't talk about it. Why?
09:00AM 04/17/13
Article
FDA Loosens Restrictions on Vivus Weight-Loss Pill
Vivus' Qsymia will now be available at retail pharmacies.
02:44PM 04/16/13
Article
Acorda Drug Helps Stroke Patients Walk Better
Acorda is seeking to expand the use of Ampyra beyond multiple sclerosis.
07:55AM 04/15/13
Article
Acadia Plans Early FDA Filing Of Parkinson's Drug
Acadia will no longer need to run a confirmatory study of pimavanserin before seeking approval.
07:28AM 04/11/13
Article
Large Vivus Shareholder Seeks More Change
A favorable FDA ruling on Qsymia's distribution is not enough for First Manhattan.
10:39AM 04/10/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
